{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:04:05Z","timestamp":1793059445877,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s13555-023-00906-2","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T03:03:25Z","timestamp":1678331005000},"page":"1029-1038","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Short-Term Effectiveness, Safety, and Potential Predictors of Response of Secukinumab in Patients with Severe Hidradenitis Suppurativa Refractory to Biologic Therapy: A Multicenter Observational Retrospective Study"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7837-7332","authenticated-orcid":false,"given":"Pablo","family":"Fernandez-Crehuet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8432-0954","authenticated-orcid":false,"given":"Sof\u00eda","family":"Haselgruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Padial-Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorella","family":"Vasquez-Chinchay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Dolores","family":"Fernandez-Ballesteros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"L\u00f3pez-Riquelme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jimenez-Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Segura-Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisol","family":"Contreras-Steyls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovana Fernanda","family":"Osorio-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Hern\u00e1ndez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Sanchez-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Cuenca-Barrales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Arias-Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6882-2113","authenticated-orcid":false,"given":"Alejandro","family":"Molina-Leyva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"issue":"2","key":"906_CR1","first-page":"114","volume":"63","author":"EY Lee","year":"2017","unstructured":"Lee EY, Alhusayen R, Lansang P, Shear N, Yeung J. What is hidradenitis suppurativa? Can Fam Physician. 2017;63(2):114\u201320.","journal-title":"Can Fam Physician"},{"issue":"5","key":"906_CR2","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jaad.2019.08.090","volume":"82","author":"SR Goldburg","year":"2020","unstructured":"Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020;82(5):1045\u201358.","journal-title":"J Am Acad Dermatol"},{"issue":"13","key":"906_CR3","doi-asserted-by":"publisher","first-page":"6709","DOI":"10.3390\/ijerph18136709","volume":"18","author":"T Montero-Vilchez","year":"2021","unstructured":"Montero-Vilchez T, Diaz-Calvillo P, Rodriguez-Pozo JA, Cuenca-Barrales C, Martinez-Lopez A, Arias-Santiago S, et al. The burden of hidradenitis suppurativa signs and symptoms in quality of life: systematic review and meta-analysis. Int J Environ Res Public Health. 2021;18(13):6709.","journal-title":"Int J Environ Res Public Health"},{"issue":"5","key":"906_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13003","volume":"32","author":"S Vural","year":"2019","unstructured":"Vural S, G\u00fcndo\u011fdu M, Akay BN, Boyvat A, Erdem C, Ko\u00e7yi\u011fit P, et al. Hidradenitis suppurativa: clinical characteristics and determinants of treatment efficacy. Dermatol Ther. 2019;32(5): e13003.","journal-title":"Dermatol Ther"},{"issue":"3","key":"906_CR5","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/14728214.2020.1787984","volume":"25","author":"AS Folkes","year":"2020","unstructured":"Folkes AS, Hawatmeh FZ, Wong A, Kerdel FA. Emerging drugs for the treatment of hidradenitis suppurativa. Expert Opin Emerg Drugs. 2020;25(3):201\u201311.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"1","key":"906_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2021.100001","volume":"1","author":"SW Jiang","year":"2021","unstructured":"Jiang SW, Whitley MJ, Mariottoni P, Jaleel T, MacLeod AS. Hidradenitis suppurativa: host-microbe and immune pathogenesis underlie important future directions. JID Innovations. 2021;1(1): 100001.","journal-title":"JID Innovations"},{"issue":"1","key":"906_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1177\/12034754211035667","volume":"26","author":"N Kashetsky","year":"2022","unstructured":"Kashetsky N, Mufti A, Alabdulrazzaq S, Lytvyn Y, Sachdeva M, Rahat A, et al. Treatment outcomes of IL-17 inhibitors in hidradenitis suppurativa: a systematic review. J Cutan Med Surg. 2022;26(1):79\u201386.","journal-title":"J Cutan Med Surg"},{"key":"906_CR8","doi-asserted-by":"publisher","unstructured":"Kimball AB, Jemec GBE, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. The Lancet. 2023. https:\/\/doi.org\/10.1016\/S0140-6736(23)00022-3","DOI":"10.1016\/S0140-6736(23)00022-3"},{"issue":"3","key":"906_CR9","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/bjd.17822","volume":"181","author":"L Prussick","year":"2019","unstructured":"Prussick L, Rothstein B, Joshipura D, Saraiya A, Turkowski Y, Abdat R, et al. Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa. Br J Dermatol. 2019;181(3):609\u201311.","journal-title":"Br J Dermatol"},{"issue":"6","key":"906_CR10","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/j.jaad.2020.02.005","volume":"82","author":"RG Casseres","year":"2020","unstructured":"Casseres RG, Prussick L, Zancanaro P, Rothstein B, Joshipura D, Saraiya A, et al. Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial. J Am Acad Dermatol. 2020;82(6):1524\u20136.","journal-title":"J Am Acad Dermatol"},{"key":"906_CR11","doi-asserted-by":"crossref","unstructured":"Reguia\u00ef Z, Fougerousse AC, Maccari F, B\u00e9cherel PA. Effectiveness of secukinumab in hidradenitis suppurativa: an open study (20 cases). J Eur Acad Dermatol Venereol. 2020;34(11):e750\u20131.","DOI":"10.1111\/jdv.16605"},{"key":"906_CR12","doi-asserted-by":"crossref","unstructured":"Ribero S, Ramondetta A, Fabbrocini G, Bettoli V, Potenza C, Chiricozzi A, et al. Effectiveness of secukinumab in the treatment of moderate\u2013severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real\u2010life setting. Acad Dermatol Venereol. 2021;35(7):e441\u20132.","DOI":"10.1111\/jdv.17178"},{"key":"906_CR13","doi-asserted-by":"crossref","unstructured":"Melgosa Ramos FJ, Garc\u00eda Ruiz R, Est\u00e9banez Corrales A, Mateu Puchades A. Long-term secukinumab efficacy in patients with moderate to severe hidradenitis suppurativa: a retrospective single-centre case series (23 patients). J Eur Acad Dermatol Venereol. 2022.","DOI":"10.1111\/jdv.18685"},{"issue":"5","key":"906_CR14","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/bjd.15748","volume":"177","author":"CC Zouboulis","year":"2017","unstructured":"Zouboulis CC, Tzellos T, Kyrgidis A, Jemec GBE, Bechara FG, Giamarellos-Bourboulis EJ, et al. Development and validation of the International Hidradenitis Suppurativa severity score system (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177(5):1401\u20139.","journal-title":"Br J Dermatol"},{"key":"906_CR15","doi-asserted-by":"crossref","unstructured":"Kimball AB, Sobell JM, Zouboulis CC, Gu Y, Williams DA, Sundaram M, et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol. 2016;30(6):989\u201394.","DOI":"10.1111\/jdv.13216"},{"issue":"4","key":"906_CR16","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/jdv.12966","volume":"29","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juh\u00e1sz I, et al. European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"906_CR17","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41391-021-00328-1","volume":"24","author":"DE Spratt","year":"2021","unstructured":"Spratt DE, Shore N, Sartor O, Rathkopf D, Olivier K. Treating the patient and not just the cancer: therapeutic burden in prostate cancer. Prostate Cancer Prostatic Dis. 2021;24(3):647\u201361.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"906_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13456","volume":"33","author":"T Montero-Vilchez","year":"2020","unstructured":"Montero-Vilchez T, Martinez-Lopez A, Salvador-Rodriguez L, Arias-Santiago S, Molina-Leyva A. The use of guselkumab 100 mg every 4 weeks on patients with hidradenitis suppurativa and a literature review. Dermatol Ther. 2020;33(3): e13456.","journal-title":"Dermatol Ther"},{"issue":"5","key":"906_CR19","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.jaad.2020.05.007","volume":"83","author":"JW Frew","year":"2020","unstructured":"Frew JW, Navrazhina K, Grand D, Sullivan-Whalen M, Gilleaudeau P, Garcet S, et al. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: an open-label cohort study. J Am Acad Dermatol. 2020;83(5):1341\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"906_CR20","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1080\/09546634.2020.1755008","volume":"33","author":"T Montero-Vilchez","year":"2022","unstructured":"Montero-Vilchez T, Pozo-Rom\u00e1n T, S\u00e1nchez-Velicia L, Vega-Guti\u00e9rrez J, Arias-Santiago S, Molina-Leyva A. Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review. J Dermatolog Treat. 2022;33(1):348\u201353.","journal-title":"J Dermatolog Treat"},{"issue":"9","key":"906_CR21","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/j.1468-3083.2011.04065.x","volume":"25","author":"L Puig","year":"2011","unstructured":"Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol. 2011;25(9):1007\u201311.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"906_CR22","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1093\/rheumatology\/kew326","volume":"55","author":"P H\u00f8jgaard","year":"2016","unstructured":"H\u00f8jgaard P, Glintborg B, Kristensen LE, Gudbjornsson B, Love TJ, Dreyer L. The influence of obesity on response to tumour necrosis factor-\u03b1 inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. Rheumatol (Oxf). 2016;55(12):2191\u20139.","journal-title":"Rheumatol (Oxf)"},{"issue":"5","key":"906_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195123","volume":"13","author":"S Singh","year":"2018","unstructured":"Singh S, Facciorusso A, Singh AG, Vande Casteele N, Zarrinpar A, Prokop LJ, et al. Obesity and response to anti-tumor necrosis factor-\u03b1 agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS One. 2018;13(5): e0195123.","journal-title":"PLoS One"},{"issue":"6","key":"906_CR24","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/bjd.20971","volume":"186","author":"M Augustin","year":"2022","unstructured":"Augustin M, Reich K, Yamauchi P, Pinter A, Bagel J, Dahale S, et al. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. Br J Dermatol. 2022;186(6):942\u201354.","journal-title":"Br J Dermatol"},{"issue":"1","key":"906_CR25","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/bjd.18983","volume":"184","author":"AV Marzano","year":"2021","unstructured":"Marzano AV, Genovese G, Casazza G, Moltrasio C, Dapavo P, Micali G, et al. Evidence for a \u201cwindow of opportunity\u201d in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study. Br J Dermatol. 2021;184(1):133\u201340.","journal-title":"Br J Dermatol"},{"issue":"1","key":"906_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/bjd.19165","volume":"184","author":"CC Zouboulis","year":"2021","unstructured":"Zouboulis CC. First real-world data provide evidence for a \u201cwindow of opportunity\u201d in treatment of hidradenitis suppurativa\/acne inversa. Br J Dermatol. 2021;184(1):10\u20131.","journal-title":"Br J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-00906-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-023-00906-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-00906-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T12:43:45Z","timestamp":1680093825000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-023-00906-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["906"],"URL":"https:\/\/doi.org\/10.1007\/s13555-023-00906-2","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,9]]},"assertion":[{"value":"26 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}